| Researchers terminate trial examining aliskiren in high-risk patients - Cardiology Today |
|
|
Cardiology Today Novartis recently announced its decision to halt a trial assessing the safety and efficacy of aliskiren for treatment of hypertension in patients with type 2 diabetes and renal impairment at high risk for CV and renal events, according to a press |